CRISPR Therapeutics AG (CRSP) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
CRISPR Therapeutics AG (CRSP) Bundle
Maximize efficiency and improve precision with our (CRSP) DCF Calculator! Utilizing real data from CRISPR Therapeutics AG and customizable assumptions, this tool empowers you to forecast, analyze, and evaluate (CRSP) like an expert investor.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 289.6 | .5 | 913.1 | .4 | 371.2 | 371.4 | 371.6 | 371.9 | 372.1 | 372.3 |
| Revenue Growth, % | 0 | -99.81 | 168054.88 | -99.95 | 85038.99 | 0.05881422 | 0.05881422 | 0.05881422 | 0.05881422 | 0.05881422 |
| EBITDA | 51.5 | -345.3 | 391.5 | -649.0 | -202.7 | -144.1 | -144.2 | -144.3 | -144.3 | -144.4 |
| EBITDA, % | 17.77 | -63582.14 | 42.87 | -148850.69 | -54.61 | -38.79 | -38.79 | -38.79 | -38.79 | -38.79 |
| Depreciation | 4.7 | 9.2 | 18.0 | 24.2 | 19.8 | 155.2 | 155.3 | 155.4 | 155.5 | 155.6 |
| Depreciation, % | 1.63 | 1691.34 | 1.97 | 5544.04 | 5.34 | 41.79 | 41.79 | 41.79 | 41.79 | 41.79 |
| EBIT | 46.7 | -354.4 | 373.5 | -673.2 | -222.5 | -150.7 | -150.8 | -150.9 | -151.0 | -151.1 |
| EBIT, % | 16.14 | -65273.48 | 40.91 | -154394.72 | -59.95 | -40.58 | -40.58 | -40.58 | -40.58 | -40.58 |
| Total Cash | 943.8 | 1,690.3 | 2,379.1 | 1,815.3 | 1,693.7 | 371.4 | 371.6 | 371.9 | 372.1 | 372.3 |
| Total Cash, percent | .0 | .3 | .0 | .4 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .1 | .1 | .3 | .0 | 200.0 | 59.8 | 59.8 | 59.8 | 59.9 | 59.9 |
| Account Receivables, % | 0.03418626 | 26.52 | 0.03340339 | 0 | 53.88 | 16.09 | 16.09 | 16.09 | 16.09 | 16.09 |
| Inventories | .0 | .0 | .0 | -11.2 | .0 | -74.3 | -74.3 | -74.4 | -74.4 | -74.5 |
| Inventories, % | 0.000000345 | 0 | 0 | -2568.81 | 0 | -20 | -20 | -20 | -20 | -20 |
| Accounts Payable | 5.9 | 9.1 | 14.8 | 27.4 | 38.1 | 158.9 | 159.0 | 159.1 | 159.2 | 159.3 |
| Accounts Payable, % | 2.05 | 1674.77 | 1.62 | 6290.83 | 10.28 | 42.79 | 42.79 | 42.79 | 42.79 | 42.79 |
| Capital Expenditure | -6.7 | -18.4 | -81.7 | -37.2 | -12.0 | -159.3 | -159.4 | -159.5 | -159.6 | -159.7 |
| Capital Expenditure, % | -2.31 | -3380.85 | -8.95 | -8529.36 | -3.22 | -42.9 | -42.9 | -42.9 | -42.9 | -42.9 |
| Tax Rate, % | -1.92 | -1.92 | -1.92 | -1.92 | -1.92 | -1.92 | -1.92 | -1.92 | -1.92 | -1.92 |
| EBITAT | 46.4 | -355.3 | 371.7 | -672.8 | -226.8 | -150.4 | -150.4 | -150.5 | -150.6 | -150.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 50.3 | -361.3 | 313.5 | -661.7 | -419.4 | 180.8 | -154.5 | -154.6 | -154.6 | -154.7 |
| WACC, % | 11.74 | 11.75 | 11.74 | 11.75 | 11.75 | 11.74 | 11.74 | 11.74 | 11.74 | 11.74 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -260.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -158 | |||||||||
| Terminal Value | -1,620 | |||||||||
| Present Terminal Value | -930 | |||||||||
| Enterprise Value | -1,190 | |||||||||
| Net Debt | -151 | |||||||||
| Equity Value | -1,039 | |||||||||
| Diluted Shares Outstanding, MM | 79 | |||||||||
| Equity Value Per Share | -13.12 |
What You Will Get
- Genuine CRISPR Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for CRISPR Therapeutics AG (CRSP).
- Complete Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates to fit your analysis.
- Real-Time Valuation Updates: Automatic recalculations to evaluate the effects of changes on CRISPR Therapeutics AG (CRSP)'s fair value.
- Flexible Excel Template: Designed for quick adjustments, scenario analysis, and comprehensive projections.
- Efficient and Precise: Avoid starting from scratch while ensuring accuracy and adaptability in your financial modeling.
Key Features
- Comprehensive Data: CRISPR Therapeutics AG’s (CRSP) historical financial statements and pre-filled forecasts.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: View CRISPR’s intrinsic value recalculated instantly.
- Intuitive Visuals: Dashboard charts present valuation results and essential metrics clearly.
- Designed for Precision: A robust tool tailored for analysts, investors, and finance professionals.
How It Works
- 1. Access the Template: Download and open the Excel file containing CRISPR Therapeutics AG’s preloaded data.
- 2. Modify Assumptions: Adjust key inputs such as growth projections, WACC, and capital expenditures.
- 3. View Results Instantly: The DCF model automatically calculates intrinsic value and NPV based on your inputs.
- 4. Explore Scenarios: Evaluate various forecasts to analyze different valuation possibilities.
- 5. Present with Assurance: Deliver professional valuation insights to back your investment decisions.
Why Choose CRISPR Therapeutics AG (CRSP)?
- Innovative Solutions: Pioneering gene-editing technologies to address unmet medical needs.
- Robust Pipeline: A diverse range of therapies in development for various genetic disorders.
- Expert Team: Led by industry leaders with extensive experience in biotechnology and genetics.
- Commitment to Research: Continuous investment in R&D to drive advancements in gene therapy.
- Strong Partnerships: Collaborations with top institutions and organizations to enhance innovation.
Who Should Use CRISPR Therapeutics AG (CRSP)?
- Investors: Gain insights into cutting-edge gene-editing technologies to inform your investment strategies.
- Biotech Analysts: Streamline your research with comprehensive data on CRISPR Therapeutics' pipeline and market potential.
- Consultants: Easily modify reports and presentations to highlight CRISPR Therapeutics' innovations for clients.
- Healthcare Enthusiasts: Explore the transformative impact of gene therapy through real-life case studies and applications.
- Educators and Students: Utilize it as a resource for understanding advanced biotechnological concepts in academic settings.
What the Template Contains
- Pre-Filled Data: Contains CRISPR Therapeutics AG's historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model with automated calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on user-defined inputs.
- Key Financial Ratios: Assess CRISPR's profitability, efficiency, and leverage metrics.
- Customizable Inputs: Easily adjust revenue growth, profit margins, and tax rates.
- Clear Dashboard: Visual representations and tables summarizing essential valuation outcomes.